Clincosm LogoSign in Get a demo

lenvatinib

Showing 1 - 11 of 11
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 30, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 24, 2023

Hepatocellular Carcinoma, Lenvatinib, Tislelizumab Trial in Hangzhou (TACE, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +5 more
  • TACE
  • Tislelizumab, Lenvatinib
  • Hangzhou, Zhejiang, China
    1# Banshan East Rd. Zhejiang cancer hospital
Jun 17, 2023

Unresectable Hepatocellular Carcinoma, Pembrolizumab, Lenvatinib Trial in Taipei City (Lenvatinib/Pembrolizumab plus SBRT

Not yet recruiting
  • Unresectable Hepatocellular Carcinoma
  • +3 more
  • Lenvatinib/Pembrolizumab plus SBRT combinations
  • Taipei City, Taiawn, Taiwan
    National Taiwan University Hospital
Jan 30, 2023

Tislelizumab, Lenvatinib, TACE Trial in Nanning (Tislelizumab and Lenvatinib)

Active, not recruiting
  • Tislelizumab
  • +3 more
  • Tislelizumab and Lenvatinib
  • Nanning, Guangxi, China
    The Affiliated Cancer Hospital of Guangxi Medical University
Jan 25, 2023

Hepatocellular Carcinoma, Microwave Ablation, Liver Cancer Trial in Changsha (Microwave ablation, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • +4 more
  • Changsha, Hunan, China
    Hunan Provincial People's Hospital
Jul 8, 2022

Melanoma, Renal Cell Carcinoma, Brain Metastases Trial in New Haven (Pembrolizumab, Lenvatinib)

Recruiting
  • Melanoma
  • +6 more
  • New Haven, Connecticut
    Yale University
Feb 18, 2022

Hepatocellular Carcinoma, Radiotherapy, Lenvatinib Trial in Beijing (concurrent lenvatinib and Radiotherapy, followed lenvatinib

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • concurrent lenvatinib and Radiotherapy, followed lenvatinib maintenance
  • Beijing, Beijing, China
    Bo Chen
Dec 19, 2021

Biliary Tract Cancer, PD-1 Antibody, Gemox Trial in Shanghai (PD-1+Lenvatinib+GEMOX)

Recruiting
  • Biliary Tract Cancer
  • +3 more
  • Shanghai, China
    Zhongshan hospital
Dec 11, 2021

Intrahepatic Cholangiocarcinoma, PD1 Antibody, Lenvatinib Trial in Shanghai (Neoadjuvant treatment)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • +3 more
  • Neoadjuvant treatment
  • Shanghai, Shanghai, China
    Zhongshan hospital
Jul 5, 2021

Hepatocellular Carcinoma, Lenvatinib Trial (Lenvatinib, TACE)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib
  • (no location specified)
Jun 2, 2021